vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

VTVT has been the topic of a number of other research reports. BTIG Research reissued a “buy” rating and issued a $57.00 target price on shares of vTv Therapeutics in a research report on Wednesday, October 14th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright decreased their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Trading Up 0.7%

Shares of NASDAQ VTVT opened at $21.18 on Friday. The company has a fifty day moving average price of $29.00 and a 200 day moving average price of $33.17. The firm has a market cap of $83.45 million, a PE ratio of -23.02 and a beta of 0.28. vTv Therapeutics has a 1-year low of $20.56 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.15. Equities research analysts forecast that vTv Therapeutics will post -2.35 EPS for the current year.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. increased its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,360 shares of the biotechnology company’s stock after buying an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.